The Successive Development of Acute Myeloblastic Leukemia, Secondary non-Hodgkin's Lymphoma and Secondary Myeloid/Natural Killer Cell Acute Leukemia in a Single Patient

2004 ◽  
Vol 45 (9) ◽  
pp. 1955-1958 ◽  
Author(s):  
Zhijian Xiao ◽  
Xiaoming Sun ◽  
Liping Jing ◽  
Huishu Cheng ◽  
Yushu Hao
2020 ◽  
Vol 50 (1) ◽  
pp. 46
Author(s):  
Fadhlia Fadhlia ◽  
Benny Kurnia ◽  
Lily Setiani ◽  
Yerni Karnita ◽  
Juniar Juniar ◽  
...  

Background: Non-Hodgkin’s lymphoma (NHL) is a primary malignancy in the lymphatic system and extranodal lymphoid tissue originating from B lymphocyte cells, T lymphocytes or natural killer (NK) cells. The incidence of NHL continues to increase with various characteristics. Objective: To find out the characteristics of NHL sufferers undergoing treatment in Otorhinolaryngology Head and Neck Surgery Department of dr. Zainoel Abidin Regional General Hospital (RSUDZA), Banda Aceh from January 2015 to December 2018. Method: This was an observational descriptive study conducted at Banda Aceh RSUDZA using retrospective secondary data collection from medical records that met the inclusion criteria, in total sampling method. Result: Found 32 research subjects, dominantly male (20), the highest age range was 56-65 years (10). The main complaints were neck lumps (10) and oropharynx lumps (11). The most common NHL was from B lymphocyte cells (6). The chemotherapy regimens used are cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The most frequent side effects are anemia, hypoalbuminemia, and leukopenia. Conclusion: The results showed that NHL was most common in men with an increased incidence in the fifth decade. Neck lumps are the most common complaint. The chemotherapy regimen used is CHOP and R-CHOP.Keywords : Non-Hodgkin’s Lymphoma, chemotherapy ABSTRAK Latar belakang: Limfoma Non-Hodgkin (LNH) adalah keganasan primer pada sistem limfatik dan jaringan limfoid ekstranodal yang berasal dari sel limfosit B, limfosit T atau sel natural killer (NK). Kejadian LNH terus meningkat dengan berbagai karakteristik. Tujuan: Melihat karakteristik penderita LNH yang menjalani pengobatan di Departemen THT-KL RSUD dr. Zainoel Abidin (RSUDZA), Banda Aceh pada periode Januari 2015 sampai Desember 2018. Metode: Penelitian deskriptif observasional dengan pengambilan data sekunder secara retrospektif dari rekam medis yang memenuhi kriteria inklusi, dengan metode total sampling. Hasil: Didapatkan total subjek penelitian 32 orang, dominan pada lakilaki (20), rentang usia tertinggi antara 56-65 tahun (10). Keluhan utama terbanyak adalah benjolan di leher (10) dan benjolan orofaring (11). LNH yang berasal dari sel limfosit B paling banyak dijumpai (6). Regimen kemoterapi yang digunakan adalah cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) dan rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Efek samping paling sering adalah anemia, hipoalbuminemia dan leukopenia. Kesimpulan: Hasil penelitian menunjukkan LNH paling sering pada laki-laki dengan angka kejadian meningkat pada dekade kelima. Keluhan yang paling sering adalah benjolan di leher. Regimen kemoterapi yang digunakan adalah CHOP dan R-CHOP.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1642-1642
Author(s):  
Aneel A. Ashrani ◽  
John A. Heit ◽  
Jeffrey A. Schmoll ◽  
Sara A. Farmer ◽  
Tanya M. Petterson ◽  
...  

Abstract Background: Hematological cancer patients are at an increased risk for VTE (RR range = 12–32). However, whether VTE risk among such patients can be further stratified is uncertain. Objective: To test hematological cancer type, stage, stage progression and chemotherapy as potential risk factors for VTE among active hematological cancer patients after controlling for other previously-identified VTE risk factors. Methods: Using the resources of the Rochester Epidemiology Project, Mayo Clinic Master Diagnostic Index and Mayo Clinic Tumor Registry, we identified all Olmsted County, MN residents with active hematological cancer over the 28-year period, 1973–2000. From this prevalence cohort, we identified 86 patients with no prior VTE (controls) who were matched on age and date of hematological cancer diagnosis to 86 hematological cancer patients with incident VTE over the same time frame (cases). For all cases and controls, we reviewed the complete medical records in the community for baseline and hematological cancer-related characteristics. Hematological cancers were re-staged at the dates of the cancer and VTE diagnosis. We tested these characteristics as potential risk factors for VTE in active hematological cancer using conditional logistic regression. Results: In an initial multivariate analysis that included body mass index (BMI), hospitalization, and any infection or central venous catheter placement within 90 days prior to the VTE event, VTE was significantly associated with hospitalization (OR=6.70; p<0.001), and marginally associated with any infection (OR=2.18; p=0.09). After adjusting for the above variables, chemotherapy administered within the preceding 90 days was significantly associated with VTE (OR=4.25; p=0.02), while stage progression was marginally associated (OR=4.79; p=0.10). Compared to all other hematological cancer types, acute leukemia (OR=5.95; p=0.01) and non-Hodgkin’s lymphoma (OR=2.61; p=0.01) were associated with VTE. However, after adjusting for BMI, hospitalization, any infection and central venous catheter, only non-Hodgkin’s lymphoma was independently associated with VTE (OR=3.79, p=0.009), while acute leukemia was not (OR=2.66, p=0.35). Conclusions: Hematological cancer type (in particular, non-Hodgkin’s lymphoma and possibly acute leukemia), recent hospitalization, recent chemotherapy, and possibly stage progression and recent infection, are risk factors for VTE among patients with active hematological cancer.


Sign in / Sign up

Export Citation Format

Share Document